euro adhoc: Intercell AG / quarterly or semiannual financial statement / Intercell AG announces Q1 2008 results and update on development programs: Vaccine against Japanese Encephalitis moving toward

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

3-month report

13.05.2008

Intercell's investigational Japanese Encephalitis vaccine expected to
obtain market approval in global traveler markets in 2008 -
commercial production started

» Intercell´s manufacturing facility in Livingston receives
Manufacturer's License from MHRA for future commercial
manufacturing of the vaccine against Japanese Encephalitis » Day-80
review from EMEA (European Medicines Agency) received » FDA waives
VRPAC (Vaccines and Related Biological Products Advisory Committee)
- Pre-approval inspection of the facilities started on time and is
currently ongoing » Licensure application submitted to Australian
Therapeutic Goods Administration (TGA) - TGA grants priority review
for Intercell's vaccine candidate » Licensure application for
approval in Switzerland to Swissmedic submitted via Novartis » EU,
US and Australian market approvals expected in 2008 » Vaccine shows
excellent safety and immunogenicity in Phase II trials in children
at "half dose"

Significant progress in vaccines against hospital-acquired infections

» S. aureus: Phase II results for vaccine designed by Intercell
expected for end 2008 / early 2009 (conducted by Merck & Co., Inc.)
» Pseudomonas : Start of clinical Phase II/III trials expected for
2008 » Pneumococcus: Outstanding pre-clinical results on novel
protein-based universal vaccine published in the Journal of
Experimental Medicine; initiation of Phase I trials is planned for
later in 2008 » Acceleration of pre-clinical candidates for further
nosocomial vaccine and antibody product targets including
Klebsiella and Enterococcus

Unique clinical data for therapeutic Hepatitis C vaccine

» Therapeutic Hepatitis C vaccine candidate meets primary endpoints
in Phase II trials - data from 46 vaccinated chronic patients
reveal statistically significant viral load reduction and favorable
safety profile » Intercell and Novartis initiated co-development;
further clinical trials will include IC31® » Intercell was awarded
"The Vaccine Industry Excellence Award" in the category of "Best
New Therapeutic Vaccine" for its therapeutic Hepatitis C vaccine
candidate at the "World Vaccine Congress" in Washington D.C.

Adjuvant IC31® - Phase I Influenza trials with IC31® successfully
completed - Collaboration on Malaria - Tuberculosis cooperation
expanded

» Influenza: Intercell's adjuvant IC31® demonstrates a very good
safety and tolerability profile in first Phase I Influenza vaccine
clinical trial » Malaria: ICLL and PATH Malaria Vaccine Initiative
(MVI) initiated a new collaboration to evaluate adjuvant IC31® in
combination with malaria antigens from the US National Institutes
of Health (NIH) » Tuberculosis: TB vaccine formulated with adjuvant
IC31® and developed in a partnership between Statens Serum Institut
(SSI) and Sanofi Pasteur enters a series of further clinical trials

Strong financial and strategic position - Costs under control, fully
on track for strong increase in revenues and sustained profitability
for the full year 2008

» EUR 4.6 m net loss for Q1 2008 compared to EUR 7.1 m in Q1 2007, a
reduction of 35.2 percent » Increase in aggregate revenues - EUR
8.6 m in Q1 2008 compared to EUR 1.5 m in Q1 2007, an increase of
473.3 percent » EUR 10.4 m R&D expenses in Q1 2008 - up 41.0 percent
compared to EUR 7.4 m in Q1 2007 following progress of development
programs as planned » Strong strategic cash position: EUR 272.2 m in
liquid funds at March 31, 2008. Further EUR 40 m already
unconditionally committed for 2008. » Intercell will finance the cash
component of the acquisition of Iomai Corporation, which was
announced today, comfortably from existing reserves. Despite higher
costs through the acquisition, Intercell also expects to maintain
its target of profitability in 2008.

Key Financial Figures

TEUR 3 months ended Year ended

March 31, March 31, Dec 31,
2008 2007 2007

Revenues 8,625 1,502 53,349

Net profit/(loss) (4,617) (7,050) 5,009

Net operating cash flow (12,808) (9,635) (41,686)

Cash and available-for-
sale financial assets 272,223 86,262 287,571

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Head of Communications

Tel. +43 1 20620-303

lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market